Ann: Invex Successfully Concludes Protocol Assistance with EMA, page-73

Invex was featured today in a Small Caps article: https://*********.com.au/invex-therapeutics-phase-three-trial-repurpose-drug-brain-disorder/ OR

"Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder" (if the link doesn't appear).

They interviewed Invex executive director Dr Thomas Duthy:

"For one daily dose of reformulated Exenatide (Presendin™), chronically administered to an estimated 21,500 treatable patients, Invex estimates the annual market is worth $1.6 billion."

“Our discounted enterprise value of $25 million does not reflect Invex’s stage of development or the market opportunity of IIH, particularly when you consider the EU constitutes 60% of the addressable market for IIH and the EMA has provided protocol assistance confirming a single phase three trial will be sufficient to support an application for market approval, subject to demonstrating clinical efficacy and safety. Meanwhile we continue to progress similar discussions with the FDA” he claimed.